People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Response Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $11.9M | $20.5M | 2022 |
| Surface Logix Inc | — | Biotechnology | Seed | $4.0M | $177.6M | 2010 |
Paul Sweetnam at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Sweetnam on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Eric Keller | 1 | 6 |
| Donald Olds | 1 | 4 |
| Keith Dionne | 1 | 3 |
| W. James O'Shea | 1 | 2 |
| Michael Berendt | 1 | 2 |
| George James Whitesides | 1 | 1 |
| Dion E. Madsen | 1 | 1 |
| Bryan James Roberts | 1 | 1 |
| Marc James Rubin | 1 | 1 |
| Ivo James Staijen | 1 | 1 |
| Steven E. Gillis | 1 | 1 |
| Winston E. Henderson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.